Sitagliptin — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Type 2 Diabetes Mellitus

• Canagliflozin
• Dapagliflozin
• Dulaglutide
• Empagliflozin
• Glimepiride
• Glipizide
• Insulin Glargine
• Metformin

Other medications in Diabetes & Metabolism

• Tirzepatide
• Tolvaptan
• Acarbose
• Alogliptin
• Burosumab
• Canagliflozin (Renal)
• Cinacalcet
• Dapagliflozin (CKD)

About Sitagliptin

Sitagliptin is a widely prescribed medication for adults with type 2 diabetes, helping to manage blood sugar levels effectively. While vital for many, the cost can be a significant barrier. TheDrugClub is dedicated to making essential medications like sitagliptin affordable, offering significant savings and unparalleled convenience to our members.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Sitagliptin is approved for (FDA label)

Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use Sitagliptin tablets should not be used in patients with type 1 diabetes. Sitagliptin has not been studied in patients with a history of pancreatitis.

Source: Read the full FDA label on DailyMed. Label effective date: August 12, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Sitagliptin (FDA label)

100 mg tablets are beige, round, biconvex film-coated tablets. Engraved “S100” on one side, plain on the other side. 50 mg tablets are light beige, round, biconvex film-coated tablets. Engraved “S50” on one side, plain on the other side. 25 mg tablets are pink, round, biconvex film-coated tablets. Engraved “S25” on one side, plain on the other side. Tablets: 100 mg, 50 mg, and 25 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 58e23b30-451c-f451-e063-6394a90a35a7. SPL document ID: 58e20de7-3df2-d310-e063-6394a90abae0. Label effective date: August 12, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Sitagliptin (FDA label)

The following adverse reactions are also discussed elsewhere in the labeling: Pancreatitis [see Warnings and Precautions ( 5.1 )] Heart Failure [see Warnings and Precautions ( 5.2 )] Acute Renal Failure [see Warnings and Precautions ( 5.3 )] Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues [see Warnings and Precautions ( 5.4 )] Hypersensitivity Reactions [see Warnings and Precautions ( 5.5 )] Severe and Disabling Arthralgia [see Warnings and Precautions ( 5.6 )] Bullous Pemphigoid [see Warnings and Precautions ( 5.7 )] Adverse reactions reported in ≥5% of patients treated with sitagliptin and more commonly than in patients treated with placebo are: upper respiratory tract infection, nasopharyngitis and headache.

Source: FDA prescribing information (DailyMed). Set ID: 58e23b30-451c-f451-e063-6394a90a35a7. SPL document ID: 58e20de7-3df2-d310-e063-6394a90abae0. Label effective date: August 12, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Sitagliptin (FDA label)

History of a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis or angioedema [See Warnings and Precautions (5.5); Adverse Reactions (6.2)] . History of a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis or angioedema. ( 5.5 , 6.2 )

Source: FDA prescribing information (DailyMed). Set ID: 58e23b30-451c-f451-e063-6394a90a35a7. SPL document ID: 58e20de7-3df2-d310-e063-6394a90abae0. Label effective date: August 12, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Sitagliptin (FDA label)

Pancreatitis: There have been postmarketing reports of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. If pancreatitis is suspected, promptly discontinue sitagliptin tablets. ( 5.1 ) Heart failure: Heart failure has been observed with two other members of the DPP-4 inhibitor class. Consider risks and benefits of sitagliptin tablets in patients who have known risk factors for heart failure. Monitor patients for signs and symptoms. ( 5.2 ) Acute Renal Failure: Has been reported postmarketing, sometimes requiring dialysis. Assessment of renal function is recommended prior to initiating sitagliptin tablets and periodically thereafter. ( 5.3 ) Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues: Increased risk of hypoglycemia when used in combination with insulin and/or an insulin secretagogue.

Source: FDA prescribing information (DailyMed). Set ID: 58e23b30-451c-f451-e063-6394a90a35a7. SPL document ID: 58e20de7-3df2-d310-e063-6394a90abae0. Label effective date: August 12, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Sitagliptin (FDA label)

7.1 Insulin Secretagogues or Insulin Coadministration of sitagliptin tablets with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia. [See Warnings and Precautions ( 5.4 )] .

Source: FDA prescribing information (DailyMed). Set ID: 58e23b30-451c-f451-e063-6394a90a35a7. SPL document ID: 58e20de7-3df2-d310-e063-6394a90abae0. Label effective date: August 12, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.